Neurizon Therapeutics (ASX:NUZ) reported positive results from a preclinical study of its lead drug candidate, NUZ-001, for Amyotrophic Lateral Sclerosis (ALS), according to a Friday filing with the Australian bourse.

NUZ-001 was shown to prevent the aggregation of TAR DNA-binding protein 43 (TDP-43), a driver of ALS pathology, the filing said.

The drug candidate also improved the electrophysiological dysfunction of TDP-43 aggregation in M337V Motor Neurons. The TDP-43 M337V mutation impairs neuronal electrical activity at multiple levels.

The company plans to conduct its clinical trial of NUZ-001 early next year, Chief Executive Michael Thurn said in the filing.

Company shares fell 4% in recent Monday trade.

Price (AUD): $0.19, Change: $-0.01, Percent Change: -4.00%